Histamine H3 receptor antagonist

Novel inhibitor of PCAF bromodomain/Tat-AcK50 association

Selective A2a adenosine receptor agonist

Novel inhibitor of PCAF bromodomain/Tat-AcK50 association

Novel inhibitor of the Ap4A phosphorylase (Rv2613c) of Mycobacterium tuberculosis (Mtb)

Potent and selective antitumor agent, effectively depleting cellular Fe, resulting in transferrin receptor-1 up-regulation, ferritin down-regulation, and increased expression of the potent metastasis suppressor, N-myc downstream regulated gene-1

Novel inhibitor of the gatekeeper mutant of BCR-ABL, suppressing in vitro resistance

Novel highly potent and selective Src_%28gene%29>Src kinase inhibitor

Inhibitor of both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation

Novel highly potent and selective α4β2 nAChR antagonist

Cyclooxygenase inhibitior

Novel tumor-targeting cytotoxic agent

Novel anticancer agent, targeting PPARγ and HDAC4, being cytotoxic to CCRF-CEM cells (CC50 = 2.8 μM), inducing apoptosis, and causing DNA fragmentation, modulating the expression of c-Myc, cleaving caspase-3, and causing in vivo tumor regression in CCRF-C

Novel cellular anticancer agent, exhibiting 7.9-341.7-fold antiproliferative activities against four cell lines, Aspc-1 (human colon adenocarcinoma cells), H358 (human nonsmall cell lung cancer cells), HCT116 (human colorectal adenocarcinoma cells), and S

Novel antitubercular agent, exerting growth inhibition of Mtb during parasitism of host macrophages

Novel anti-SARS-CoV-2 agent, displaying in vitro antiviral activity with IC 50 0.016 µM and Mpro inhibition activity with IC 50 0.013 µM, showing potent activity against human TMPRSS2 and furin enzymes with IC 50 0.05, and 0.08 µM, respectively

Novel antioxidant, binding copper in a unique manner compared to other chelates proposed to treat Alzheimer's disease and protecting HT-22 neuronal cells from cell death induced by Aβ + copper(II)

Novel anti-MERS-CoV agent against virus-infected Huh7 cells

Novel idebenone analog, demonstrating significantly higher potency ex vivo, and significantly lower cytotoxicity, than idebenone in the treatment of Leber's Hereditary Optic Neuropathy (LHON)

Novel antileishmanial agent, strongly inhibiting recombinant CYP51 from L. donovani, displaying activity against L. donovani intracellular amastigotes with an IC50 value of 0.53 μM

Novel antileishmanial agent against L. amazonensis promastigotes (IC 50 = 15.52 ± 3.782 μM) and intracellular amastigotes (IC 50 = 4.10 ± 1.136 μM), 50% cytotoxicity concentration at 84.01 ± 3.064 μM against BALB/c peritoneal macrophages, and 20.49-fold s

Novel antifungal agent, inhibiting C. neoformans growth at submicromolar levels, being effective against fluconazole-resistant C. neoformans and a clinical strain of C. gattii, and being not antagonistic with currently approved antifungal

Novel broad-spectrum antifungal agent, also exhibiting good fungicidal activity against both fluconazole-sensitive and -resistant Candida albicans cells and having potent inhibition activity against Candida albicans biofilm formation and hyphal growth, in

Novel inhibitor of de novo purine biosynthesis with selectivity for cellular uptake by high affinity folate receptors and the proton-coupled folate transporter (PCFT) over the reduced folate carrier (RFC)

Novel inhibitor of de novo purine biosynthesis with selectivity for cellular uptake by high affinity folate receptors and the proton-coupled folate transporter (PCFT) over the reduced folate carrier (RFC)

Novel covalent anti-cancer toxin, targeting β-tubulin and covalently modifyng Cys239 within the colchicine binding site

Novel anticancer agent, showing most significant anti-cancer activity against prostate cancer cells with IC50 values of 8.8 µM and 9.5 µM in PC-3 and DU-145 cells, respectively

Novel Potent and Nontoxic Antibiotic Adjuvant

Analogue of the marine sponge natural product oroidin, suppresses biofilm formation and enhancing control of copper-resistant Xanthomonas euvesicatoria on pepper

Novel dose-dependent antiangiogenic agent